Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study
Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Cheng Peng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang, Changcheng Zheng, Xuliang Shen, Qi Hu, Jing Liu, Jie Jin, Jianmin Luo, Yun Zeng, Sujun Gao, Xiaohui Zhang, Xin Zhou, Qingzhi Shi, Ruixiang Xia, Xiaobao Xie, Zhongxing Jiang, Li Gao, Yuansong Bai, Yan Li, Junye Xiong, Runzi Li, Jianjun Zou, Ting Niu, Renchi Yang, Yu Hu
Topics & Concepts
MedicineAdverse effectClinical endpointStage (stratigraphy)PlaceboInternal medicineUpper respiratory tract infectionUrinary systemClinical trialRandomized controlled trialSurgeryAlternative medicinePathologyBiologyPaleontologyPlatelet Disorders and TreatmentsHeparin-Induced Thrombocytopenia and ThrombosisBlood transfusion and management